Nothing Special   »   [go: up one dir, main page]

WO2014048968A1 - Frozen confection comprising valerenic acid and one or more flavones - Google Patents

Frozen confection comprising valerenic acid and one or more flavones Download PDF

Info

Publication number
WO2014048968A1
WO2014048968A1 PCT/EP2013/069934 EP2013069934W WO2014048968A1 WO 2014048968 A1 WO2014048968 A1 WO 2014048968A1 EP 2013069934 W EP2013069934 W EP 2013069934W WO 2014048968 A1 WO2014048968 A1 WO 2014048968A1
Authority
WO
WIPO (PCT)
Prior art keywords
frozen confection
valerenic acid
gaba
group
flavones
Prior art date
Application number
PCT/EP2013/069934
Other languages
French (fr)
Inventor
Benjamin John MADDISON
Charlotte Mary WALDEN
Joy Elizabeth Wilkinson
Original Assignee
Unilever Plc
Unilever N.V.
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc, Unilever N.V., Conopco, Inc., D/B/A Unilever filed Critical Unilever Plc
Publication of WO2014048968A1 publication Critical patent/WO2014048968A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/42—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/038—Gamma-amino butyric acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2116—Flavonoids, isoflavones

Definitions

  • the present invention relates to frozen confectionery products, in particular to frozen confectionery products that have a relaxatory effect when consumed.
  • GABA Gamma-aminobutyric acid
  • JP 2005 / 348656 discloses a food or beverage having a relaxatory effect, the product disclosed therein contains elevated levels of GABA.
  • Frozen confections such as ice cream have been shown to have an effect on the orbitofrontal cortex, a part of the brain that is known to activate when people enjoy themselves (see for example "How ice cream tickles your brain", The Guardian, April 29 2005).
  • the combination of ice cream with the psycho-pharmacological effect of GABA is therefore an especially suitable means for providing a relaxing food product.
  • GABA acts through the potentiation of the GABA receptor.
  • This receptor is integral to the mechanism by which GABA is capable of enhancing mood.
  • the GABA molecule is believed to bind to the extracellular part of the GABA-alpha subunit of the GABAa receptor, thereby opening a transmembrane chloride ion-selective pore. Actives that are capable of enhancing the potentiation of this receptor are highly sought after.
  • Benzodiazepines are one such class of GABA receptor enhancing actives. They act upon the GABA receptor and are used for anti-anxiety treatments. In vitro assays which measure the current of ions through the GABA receptor channel have shown that benzodiazepines are capable of enhancing the potentiation of the receptor. The benzodiazepines do not interact with the binding site of GABA itself, they interact with another site on the receptor. Therefore these chemicals are capable of enhancing the ability of GABA to activate the GABA receptor.
  • benzodiazepines are widely known as psychoactive drugs. Such pharmacological actives are not acceptable to everyday consumers, nor are they suitable ingredients for frozen confections.
  • Valerenic acid is a naturally occurring chemical and is a constituent of the essential oil of the Valerian plant. Valerenic acid is believed to act on the GABA receptor in a similar way to the benzodiazepines, that is to say it acts upon the GABA-alpha subunit of the receptor but on a different site to the GABA compound. Valerenic acid also enhances the potentiation of the GABA receptor and since it is a naturally occurring substance which can be obtained the Valerian herb it is a much more suitable ingredient to use in frozen confections. The combination of ice cream and valerenic acid is therefore an especially suitable means for providing a relaxing food product. However, there remains a need to enhance the performance of valerenic acid in such products. Moreover, there remains a need for natural components that are capable of synergistically enhancing the performance of valerenic acid.
  • the present invention provides a frozen confection comprising
  • the A-ring has at least one R1 group which is a -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
  • R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof;
  • - R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or
  • the A-ring has four R1 groups.
  • the A-ring has two R1 groups attached to carbon atoms 8 and 6.
  • the A-ring has one R1 group attached to either carbon atom 8 or 6.
  • the R2 group is an -OH group, more preferably an -H group.
  • the R3 group is an -OCH3 group, more preferably an -OH group, most preferably an -H group.
  • the flavone is selected from the group consisting of Wogonin, Hispidulin, and Tangeretin.
  • the frozen confection comprises at least 0.0001 wt% valerenic acid, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%.
  • the frozen confection comprises at most 0.025 wt% valerenic acid, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%.
  • the frozen confection comprises at least 0.0001 wt% of the one or more flavones,
  • the frozen confection comprises at most 0.025 wt% of the one or more flavones, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%.
  • GABA can be present endogenously and therefore need not be present in the frozen confection.
  • the product can also provide additional GABA. Therefore the frozen confection preferably contains at least 0.00001 wt% GABA, more preferably at least 0.0001 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.01 wt%.
  • the frozen confection comprises at most 0.5 wt% GABA, more preferably at most 0.1 wt%, more preferably still at most 0.05 wt%.
  • the invention provides a method for enhancing the potentiation of the GABA receptor comprising the administration of the product according to the first aspect to healthy individuals.
  • the invention provides a product for the potentiation of the GABA receptor wherein the product comprises
  • the A-ring has at least one R1 group which is an -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
  • - R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof;
  • R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or 6' and wherein the ratio of the valerenic acid to the flavone is from 20:80 to 80:20.
  • the ratio of the valerenic acid to the flavone is at least 20:80, more preferably at least 30:70, more preferably still at least 40:60, most preferably at least 45:55.
  • the ratio of the valerenic acid to the flavone is at most 80:20, more preferably at most 70:30, more preferably still at most 60:40, most preferably at most 55:45.
  • the valerenic acid and the flavone are present in approximately equal amounts.
  • the invention provides a method for the enhancement of mood wherein healthy individuals consume an effective amount of the frozen confection of the first aspect.
  • the invention provides a product for the enhancement of mood comprising the product of the third aspect.
  • GABA Gamma aminobutyric acid
  • lUPAC name: 4-aminobutanoic acid is the chief inhibitory neurotransmitter in the mammalian central nervous system.
  • GABA acts at inhibitory synapses in the brain by binding to specific transmembrane receptors in the plasma membrane of both pre- and postsynaptic neuronal processes. Binding causes the opening of ion channels to allow the flow of either negatively charged chloride ions into the cell or positively charged potassium ions out of the cell. This action results in a negative change in the transmembrane potential, usually causing hyperpolarization.
  • GABA has long been associated with mood.
  • Evidence from preclinical and clinical studies has indicated that a GABA deficit may be involved in mood disorders, particularly in depression, and that increasing GABAergic neurotransmission may exert an antidepressant effect and a mood stabilizing effect.
  • a study by Abdou et al. (“Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans.” Biofactors. 2006, Vol. 26 Issue 3, p201 -208) investigated the effect of orally administrated GABA on relaxation during stress.
  • the effect of GABA intake by 13 subjects was investigated by measuring brain waves using electroencephalograms. It was found that GABA significantly increased alpha waves and decreased beta waves (compared to water or L-theanine).
  • GABA mediates fast synaptic inhibition by interaction with the GABA type A (GABAa) receptor.
  • GABAa receptors are assembled from individual subunits forming a pentameric structure.
  • Nineteen isoforms of mammalian GABAa receptor subunits have been cloned and the subunit composition determines the GABA sensitivity and the pharmacological properties of the GABAa receptor.
  • Binding sites for GABA are thought to be located at subunit interfaces. Studies suggest that the binding pocket of GABA occurs at the interfaces between alpha and beta subunits.
  • GABAa channels are modulated by numerous structurally distinct substances including clinically important drugs such as barbiturates and various general anaesthetics and also by several compounds of plant origin.
  • Benzodiazepines are one such type of active that are capable of modulating the GABAa receptor and are widely used for anti-anxiety treatments. Benzodiazepines work by increasing the efficiency of GABA to decrease the excitability of neurons. This reduces the communication between neurons and, therefore, has a calming effect on many of the functions of the brain. Benzodiazepines have been shown to enhance the modulation of the receptor as demonstrated with in vitro assays which measure the current of ions through the channel. Benzodiazepines do not interact with the actual binding site of GABA itself, they interact with another site on the receptor. It is therefore clear that actives such as benzodiazepines which are capable of modulating the GABAa receptor play an important role in providing relaxation and the enhancement of mood.
  • frozen confections such as ice cream is therefore another suitable means for providing a relaxing food product.
  • the term "frozen confection” means a sweet-tasting fabricated foodstuff intended for consumption in the frozen state (i.e. under conditions wherein the temperature of the foodstuff is less than 0°C, and preferably under conditions wherein the foodstuff comprises significant amounts of ice).
  • Frozen confections include ice cream, sorbet, sherbet, frozen yoghurt, water ice, milk ice and the like.
  • the frozen confection is an ice cream, milk ice, frozen yoghurt, or sherbet.
  • Frozen confection may be aerated, i.e. subjected to deliberate steps such as whipping to increase the gas content. Overrun is defined by the following equation:
  • the overrun is from 30 to 200%, more preferably from 50 to 150%. Overrun is measured at atmospheric pressure.
  • Valerenic acid ((2E)-3-[(4S ! 7R ! 7aR)-3 ! 7-dimethyl-2 ! 4 ! 5 ! 6 ! 7,7a-hexahydro-1 H-inden-4-yl]- 2-methylacrylic acid) is one such natural alternative.
  • Valerenic acid is the major constituent of valerian, one of the most commonly used herbal medicines for the treatment of anxiety and insomnia.
  • Valerian has anxiolytic, tranquilizing, and sleep inducing effects that have been demonstrated in both animal studies and clinical trials.
  • Valerenic acid is believed to induce these effects by enhancing the potentiation of the GABAa receptor and is believed to act on this receptor in a similar way to benzodiazepines. Since valerenic acid is a naturally occurring substance it is more acceptable to consumers than actives such as benzodiazepines and is therefore a suitable ingredient to use in frozen confections.
  • valerenic acid has on the potentiation of the GABAa receptor and hence enhance the effect that GABA has on mood.
  • Flavones are a sub-class of flavonoids and are based on the backbone of 2-phenylchromen-4-one (2-phenyl-1 -benzopyran-4- one) shown below:
  • the flavones that have been found to enhance the effect of valerenic acid have at least one methoxy group (-OCH3) on the A-ring. More particularly, the invention utilises flavones having at least one-OCH3 group attached to any of carbon atoms 5, 6, 7, or 8 of the A-ring; an -H, -OH, an alkyl, an alkene, or derivatives thereof at position 2 of the C-Ring; and an -H, -OH, or -OCH3 attached to any of carbon atoms 2', 3', 4', 5', or 6' of the B-Ring.
  • the A-ring has a methoxy group attached to each of carbon atoms 5, 6, 7, & 8.
  • the flavone has a methoxy group attached to either or both of carbon atoms 6 and 8 of the A-ring.
  • Such preferred flavones are futher exemplified by and Hispidulin (5,7,4'-trihydroxy-6- methoxy-flavone):
  • the invention provides a frozen confection containing at least 0.00005 wt% valerenic acid.
  • the frozen confection contains at least 0.0001 wt% valerenic acid, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%.
  • the frozen confection contains at most 0.05wt%, valerenic acid.
  • the frozen confection contains at most 0.025 wt% valerenic acid, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%.
  • the performance of the product containing valerenic acid will be enhanced by the addition of the specific type of flavones set out above. This is demonstrated in the examples which follow wherein the effects of the flavones are assessed using in vitro assays. In these assays, micro-molar amounts of the flavones were used to determine their ability to enhance the effect of valerenic acid.
  • the frozen confection should contain at least 0.00005 wt% of the flavones, preferably at least 0.0001 wt%, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%.
  • the frozen confection contains at most 0.05 wt% of these flavones, preferably at most 0.025 wt%, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%.
  • GABA should be present in order to interact with the GABAa receptor in combination with the flaovones and the valerenic acid.
  • GABA can be present endogenously in the body of the consumer and therefore need not be present in the product of the invention.
  • the product may also provide additional GABA in order to facilitate the GABA-related mood effects. Therefore the frozen confection preferably contains at least 0.00001 wt% GABA, more preferably at least 0.0001 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.01 wt%.
  • frozen confections are a particularly suitable product form for this invention, it is not necessarily the only one. Therefore this present invention also provides a product which comprises valerenic acid in combination with the specific type of flavones set out above in a ratio of from 20:80 to 80:20. This product is capable of potentiating the GABAa receptor and may be incorporated into other product types such as foods and beverages.
  • the invention will now be further explained in the following examples.
  • GABAA GABAA-CHO, automated patch- clamp, agonist
  • the control agonist response was defined as the response of the GABAa receptor to an EC20 concentration of muscimol, Muscimol was used as the mimetic of GABA.
  • the "% of control against agonist response” was calculated by comparing the response of the GABAa receptor to the test compounds against the response to muscimol (i.e. the response of the GABAa receptor to this GABA mimetic was used as the "baseline” of 0%). If the "% of control against agonist response" is greater than the baseline of 0% (i.e. greater than the induction caused by muscimol alone) it indicates that the test compound exhibits potentiation of the GABAa receptor. If the "% of control against agonist response" is less than 0% it indicates an antagonist effect. All assays were performed in triplicate, the mean values are given below.
  • the effect is deemed to be synergistic.
  • IE if C>(A+B) then the effect is synergistic.
  • valerenic acid in combination with wogonin and hispidulin was tested at 5.0uM concentrations. The results are shown in Table 1
  • valerenic acid in combination with wogonin and hispidulin Table 1 shows that valerenic acid in combination with wogonin gave a higher (i.e. synergistic) response than the sum of valerenic acid and wogonin alone (88 > (21 .5+25)). It also shows that valerenic acid in combination with hispidulin gave a higher response than the sum of valerenic acid and hispidulin alone (71 > (21 .5+7)).
  • valerenic acid in combination with tangeretin was tested at 5.0uM concentrations. The results are shown in Table 2.
  • Table 2 shows that valerenic acid in combination with tangeretin gave a higher response (i.e. synergistic) than the sum of valerenic acid and tangeretin alone (123 > (43+56)).
  • valerenic acid in combination with apigenin, chrysin, naringenin, and pinocembrin was tested at 5.0uM concentrations. The results are shown in Table 3. It is notable that:
  • Naringenin and pinocembrin are both flavanones - they have no double bond between carbons 2 and 3 of the C-ring; and Although apigenin and chrysin are both flavones, they have no methoxy groups the A-ring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A frozen confection comprising from 0.00005 to 0.05 wt% valerenic acid; and from 0.00005 to 0.05 wt% of one or more flavones having the structure wherein the A-ring has at least one R1 group which is a -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8; R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof; and R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or 6' is provided

Description

FROZEN CONFECTION COMPRISING VALERENIC ACID AND
ONE OR MORE FLAVONES
Technical Field of Invention
The present invention relates to frozen confectionery products, in particular to frozen confectionery products that have a relaxatory effect when consumed.
Background to Invention
Gamma-aminobutyric acid (GABA) is known to be a psycho-pharmacologically active compound (Smit et al., Psychopharmacology 2004, 176, pp 412-419) and as such plays a role in the enhancement of mood. JP 2005 / 348656 discloses a food or beverage having a relaxatory effect, the product disclosed therein contains elevated levels of GABA. Frozen confections such as ice cream have been shown to have an effect on the orbitofrontal cortex, a part of the brain that is known to activate when people enjoy themselves (see for example "How ice cream tickles your brain", The Guardian, April 29 2005). The combination of ice cream with the psycho-pharmacological effect of GABA is therefore an especially suitable means for providing a relaxing food product.
GABA acts through the potentiation of the GABA receptor. This receptor is integral to the mechanism by which GABA is capable of enhancing mood. The GABA molecule is believed to bind to the extracellular part of the GABA-alpha subunit of the GABAa receptor, thereby opening a transmembrane chloride ion-selective pore. Actives that are capable of enhancing the potentiation of this receptor are highly sought after.
Benzodiazepines are one such class of GABA receptor enhancing actives. They act upon the GABA receptor and are used for anti-anxiety treatments. In vitro assays which measure the current of ions through the GABA receptor channel have shown that benzodiazepines are capable of enhancing the potentiation of the receptor. The benzodiazepines do not interact with the binding site of GABA itself, they interact with another site on the receptor. Therefore these chemicals are capable of enhancing the ability of GABA to activate the GABA receptor.
However, benzodiazepines are widely known as psychoactive drugs. Such pharmacological actives are not acceptable to everyday consumers, nor are they suitable ingredients for frozen confections.
Fortunately, alternative actives are also capable of increasing the potentiation of the GABA receptor, for example valerenic acid. Valerenic acid is a naturally occurring chemical and is a constituent of the essential oil of the Valerian plant. Valerenic acid is believed to act on the GABA receptor in a similar way to the benzodiazepines, that is to say it acts upon the GABA-alpha subunit of the receptor but on a different site to the GABA compound. Valerenic acid also enhances the potentiation of the GABA receptor and since it is a naturally occurring substance which can be obtained the Valerian herb it is a much more suitable ingredient to use in frozen confections. The combination of ice cream and valerenic acid is therefore an especially suitable means for providing a relaxing food product. However, there remains a need to enhance the performance of valerenic acid in such products. Moreover, there remains a need for natural components that are capable of synergistically enhancing the performance of valerenic acid. Statement of Invention
We have now found that a specific subset of chemicals from the flavone group which comprise at least one methoxy group on the A-ring are capable of synergistically enhancing the ability of valerenic acid to increase the potentiation of the GABA receptor.
Accordingly, in a first aspect the present invention provides a frozen confection comprising
from 0.00005 to 0.05 wt% valerenic acid; and
from 0.00005 to 0.05 wt% of one or more flavones having the structure
Figure imgf000005_0001
wherein
the A-ring has at least one R1 group which is a -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof; and
- R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or
6'.
Preferably the A-ring has four R1 groups. Preferably the A-ring has two R1 groups attached to carbon atoms 8 and 6. Preferably the A-ring has one R1 group attached to either carbon atom 8 or 6.
Preferably the R2 group is an -OH group, more preferably an -H group.
Preferably the R3 group is an -OCH3 group, more preferably an -OH group, most preferably an -H group. Preferably the flavone is selected from the group consisting of Wogonin, Hispidulin, and Tangeretin.
Preferably the frozen confection comprises at least 0.0001 wt% valerenic acid, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%.
Preferably the frozen confection comprises at most 0.025 wt% valerenic acid, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%.
Preferably the frozen confection comprises at least 0.0001 wt% of the one or more flavones,
more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%. Preferably the frozen confection comprises at most 0.025 wt% of the one or more flavones, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%. GABA can be present endogenously and therefore need not be present in the frozen confection. However, the product can also provide additional GABA. Therefore the frozen confection preferably contains at least 0.00001 wt% GABA, more preferably at least 0.0001 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.01 wt%.
Preferably the frozen confection comprises at most 0.5 wt% GABA, more preferably at most 0.1 wt%, more preferably still at most 0.05 wt%.
In a second aspect, the invention provides a method for enhancing the potentiation of the GABA receptor comprising the administration of the product according to the first aspect to healthy individuals.
In a third aspect, the invention provides a product for the potentiation of the GABA receptor wherein the product comprises
- A combination of valerenic acid and one or more flavones having the structure
Figure imgf000008_0001
wherein
the A-ring has at least one R1 group which is an -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
- R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof; and
R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or 6' and wherein the ratio of the valerenic acid to the flavone is from 20:80 to 80:20.
Preferably the ratio of the valerenic acid to the flavone is at least 20:80, more preferably at least 30:70, more preferably still at least 40:60, most preferably at least 45:55.
Preferably the ratio of the valerenic acid to the flavone is at most 80:20, more preferably at most 70:30, more preferably still at most 60:40, most preferably at most 55:45. Preferably the valerenic acid and the flavone are present in approximately equal amounts. In a fourth aspect, the invention provides a method for the enhancement of mood wherein healthy individuals consume an effective amount of the frozen confection of the first aspect. In a fifth aspect, the invention provides a product for the enhancement of mood comprising the product of the third aspect.
Detailed Description of the Invention
Gamma aminobutyric acid (GABA, lUPAC name: 4-aminobutanoic acid) is the chief inhibitory neurotransmitter in the mammalian central nervous system. In vertebrates, GABA acts at inhibitory synapses in the brain by binding to specific transmembrane receptors in the plasma membrane of both pre- and postsynaptic neuronal processes. Binding causes the opening of ion channels to allow the flow of either negatively charged chloride ions into the cell or positively charged potassium ions out of the cell. This action results in a negative change in the transmembrane potential, usually causing hyperpolarization.
GABA has long been associated with mood. Evidence from preclinical and clinical studies has indicated that a GABA deficit may be involved in mood disorders, particularly in depression, and that increasing GABAergic neurotransmission may exert an antidepressant effect and a mood stabilizing effect. For example, a study by Abdou et al. ("Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans." Biofactors. 2006, Vol. 26 Issue 3, p201 -208) investigated the effect of orally administrated GABA on relaxation during stress. The effect of GABA intake by 13 subjects was investigated by measuring brain waves using electroencephalograms. It was found that GABA significantly increased alpha waves and decreased beta waves (compared to water or L-theanine). The findings indicated that GABA induces relaxation and reduce anxiety. It is therefore clear that GABA plays a role in the enhancement of mood.
GABA mediates fast synaptic inhibition by interaction with the GABA type A (GABAa) receptor. GABAa receptors are assembled from individual subunits forming a pentameric structure. Nineteen isoforms of mammalian GABAa receptor subunits have been cloned and the subunit composition determines the GABA sensitivity and the pharmacological properties of the GABAa receptor. Binding sites for GABA are thought to be located at subunit interfaces. Studies suggest that the binding pocket of GABA occurs at the interfaces between alpha and beta subunits. GABAa channels are modulated by numerous structurally distinct substances including clinically important drugs such as barbiturates and various general anaesthetics and also by several compounds of plant origin.
Benzodiazepines are one such type of active that are capable of modulating the GABAa receptor and are widely used for anti-anxiety treatments. Benzodiazepines work by increasing the efficiency of GABA to decrease the excitability of neurons. This reduces the communication between neurons and, therefore, has a calming effect on many of the functions of the brain. Benzodiazepines have been shown to enhance the modulation of the receptor as demonstrated with in vitro assays which measure the current of ions through the channel. Benzodiazepines do not interact with the actual binding site of GABA itself, they interact with another site on the receptor. It is therefore clear that actives such as benzodiazepines which are capable of modulating the GABAa receptor play an important role in providing relaxation and the enhancement of mood.
Similarly, ice cream has been shown to have an effect on the orbitofrontal cortex, a part of the brain that is known to activate when people enjoy themselves. The use of frozen confections such as ice cream is therefore another suitable means for providing a relaxing food product. The term "frozen confection" means a sweet-tasting fabricated foodstuff intended for consumption in the frozen state (i.e. under conditions wherein the temperature of the foodstuff is less than 0°C, and preferably under conditions wherein the foodstuff comprises significant amounts of ice). Frozen confections include ice cream, sorbet, sherbet, frozen yoghurt, water ice, milk ice and the like. Preferably the frozen confection is an ice cream, milk ice, frozen yoghurt, or sherbet. Frozen confection may be aerated, i.e. subjected to deliberate steps such as whipping to increase the gas content. Overrun is defined by the following equation:
density of premix - density of frozen confection
overrun (%) = χ 100
density of frozen confection
Preferably the overrun is from 30 to 200%, more preferably from 50 to 150%. Overrun is measured at atmospheric pressure.
It is therefore advantageous to combine a GABAa receptor modulator with a frozen confection to deliver mood benefits. However, it is not possible to provide consumers with frozen confections comprising pharmacological actives such as benzodiazepine. Natural alternatives are therefore preferred. Valerenic acid ((2E)-3-[(4S!7R!7aR)-3!7-dimethyl-2!4!5!6!7,7a-hexahydro-1 H-inden-4-yl]- 2-methylacrylic acid) is one such natural alternative. Valerenic acid is the major constituent of valerian, one of the most commonly used herbal medicines for the treatment of anxiety and insomnia. Valerian has anxiolytic, tranquilizing, and sleep inducing effects that have been demonstrated in both animal studies and clinical trials. Valerenic acid is believed to induce these effects by enhancing the potentiation of the GABAa receptor and is believed to act on this receptor in a similar way to benzodiazepines. Since valerenic acid is a naturally occurring substance it is more acceptable to consumers than actives such as benzodiazepines and is therefore a suitable ingredient to use in frozen confections.
Nevertheless it would still be preferred to enhance the effect that valerenic acid has on the potentiation of the GABAa receptor and hence enhance the effect that GABA has on mood. Moreover, it is sought to provide natural components that are capable of synergistically enhancing the performance of valerenic acid.
It has now been found that a specific type of falvones are capable of synergistically enhancing the effect provided by valerenic acid. Flavones are a sub-class of flavonoids and are based on the backbone of 2-phenylchromen-4-one (2-phenyl-1 -benzopyran-4- one) shown below:
Figure imgf000013_0001
In particular the flavones that have been found to enhance the effect of valerenic acid have at least one methoxy group (-OCH3) on the A-ring. More particularly, the invention utilises flavones having at least one-OCH3 group attached to any of carbon atoms 5, 6, 7, or 8 of the A-ring; an -H, -OH, an alkyl, an alkene, or derivatives thereof at position 2 of the C-Ring; and an -H, -OH, or -OCH3 attached to any of carbon atoms 2', 3', 4', 5', or 6' of the B-Ring. In a preferred embodiment, the A-ring has a methoxy group attached to each of carbon atoms 5, 6, 7, & 8. In a particularly preferred embodiment the flavone has a methoxy group attached to either or both of carbon atoms 6 and 8 of the A-ring.
Such preferred flavones are exemplified by Tangeretin (5,6,7,8,4'-pentamethoxy-flavone):
Figure imgf000013_0002
O O Such preferred flavones are also exemplified by Wogonin (5,7-dihydroxy-8-methoxy- flavone):
Figure imgf000014_0001
Such preferred flavones are futher exemplified by and Hispidulin (5,7,4'-trihydroxy-6- methoxy-flavone):
Figure imgf000014_0002
As set out above, the combination of the natural GABAa receptor modulator valerenic acid with frozen confections (which have been shown to have an effect on the orbitofrontal cortex) is particularly attractive. Accordingly, the invention provides a frozen confection containing at least 0.00005 wt% valerenic acid. Preferably the frozen confection contains at least 0.0001 wt% valerenic acid, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%. The frozen confection contains at most 0.05wt%, valerenic acid. Preferably the frozen confection contains at most 0.025 wt% valerenic acid, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%. The performance of the product containing valerenic acid will be enhanced by the addition of the specific type of flavones set out above. This is demonstrated in the examples which follow wherein the effects of the flavones are assessed using in vitro assays. In these assays, micro-molar amounts of the flavones were used to determine their ability to enhance the effect of valerenic acid. In order to determine what levels of the flavones must be consumed in a frozen confection in order to deliver the necessary levels of the flavones in the blood plasma, an ADME-toxocolgy analysis was carried out. Accordingly, it was ascertained that the frozen confection should contain at least 0.00005 wt% of the flavones, preferably at least 0.0001 wt%, more preferably at least 0.0005 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.005 wt%. The frozen confection contains at most 0.05 wt% of these flavones, preferably at most 0.025 wt%, more preferably at most 0.02 wt%, more preferably still at most 0.015 wt%, yet more preferably still at most 0.01 wt%. In order for the product of the invention to deliver a GABA-related enhancement of mood it is clear that GABA should be present in order to interact with the GABAa receptor in combination with the flaovones and the valerenic acid. GABA can be present endogenously in the body of the consumer and therefore need not be present in the product of the invention. However, the product may also provide additional GABA in order to facilitate the GABA-related mood effects. Therefore the frozen confection preferably contains at least 0.00001 wt% GABA, more preferably at least 0.0001 wt%, more preferably still at least 0.001 wt%, yet more preferably still at least 0.01 wt%.
Although frozen confections are a particularly suitable product form for this invention, it is not necessarily the only one. Therefore this present invention also provides a product which comprises valerenic acid in combination with the specific type of flavones set out above in a ratio of from 20:80 to 80:20. This product is capable of potentiating the GABAa receptor and may be incorporated into other product types such as foods and beverages. The invention will now be further explained in the following examples.
EXAMPLES
Cellular assays were carried out using the GABAA (GABAA-CHO, automated patch- clamp, agonist) functional assay as described in Sieghart, W. (1995) Pharmacological Reviews, 47(2): 181-234.
The control agonist response was defined as the response of the GABAa receptor to an EC20 concentration of muscimol, Muscimol was used as the mimetic of GABA. The "% of control against agonist response" was calculated by comparing the response of the GABAa receptor to the test compounds against the response to muscimol (i.e. the response of the GABAa receptor to this GABA mimetic was used as the "baseline" of 0%). If the "% of control against agonist response" is greater than the baseline of 0% (i.e. greater than the induction caused by muscimol alone) it indicates that the test compound exhibits potentiation of the GABAa receptor. If the "% of control against agonist response" is less than 0% it indicates an antagonist effect. All assays were performed in triplicate, the mean values are given below.
Assays were carried out to asses the enhanced response provided by valerenic acid. In these assays the effect of valerenic acid alone and in combination with a range of flavones was assessed. Synergistic effects were defined as follows: The response provided by valerenic acid alone is denoted TV.
The response provided by the flavone alone is denoted 'Β'.
The response provided by the combination of the valerenic acid and the flavone is denoted 'C
If the response provided by the combination of the valerenic acid and the flavone is greater than the sum of the response provided by valerenic acid alone plus the response provided by the flavone alone then the effect is deemed to be synergistic. IE, if C>(A+B) then the effect is synergistic.
In a first experiment, valerenic acid in combination with wogonin and hispidulin was tested at 5.0uM concentrations. The results are shown in Table 1
Figure imgf000017_0001
Table 1 - results of experiment: valerenic acid in combination with wogonin and hispidulin Table 1 shows that valerenic acid in combination with wogonin gave a higher (i.e. synergistic) response than the sum of valerenic acid and wogonin alone (88 > (21 .5+25)). It also shows that valerenic acid in combination with hispidulin gave a higher response than the sum of valerenic acid and hispidulin alone (71 > (21 .5+7)).
In a second experiment, valerenic acid in combination with tangeretin was tested at 5.0uM concentrations. The results are shown in Table 2.
Figure imgf000018_0001
Table 2 - results of experiment: valerenic acid in combination with tangeretin
Table 2 shows that valerenic acid in combination with tangeretin gave a higher response (i.e. synergistic) than the sum of valerenic acid and tangeretin alone (123 > (43+56)).
In a third experiment, valerenic acid in combination with apigenin, chrysin, naringenin, and pinocembrin was tested at 5.0uM concentrations. The results are shown in Table 3. It is notable that:
Naringenin and pinocembrin are both flavanones - they have no double bond between carbons 2 and 3 of the C-ring; and Although apigenin and chrysin are both flavones, they have no methoxy groups the A-ring.
Figure imgf000019_0001
Table 3 - results of experiment: valerenic acid in combination with apigenin, chrysin, naringenin, and pinocembrin
It can clearly be seen that no synergistic effects were achieved through the combination of valeranic acid with the compounds shown in table 3. In fact all of these compounds actually reduced the effect of valerenic acid. From the foregoing data it has been demonstrated that only a very specific subset of the flavone family are capable of synergistically enhancing the modulation of the GABAa receptor by valerenic acid.

Claims

Claims
1. A frozen confection comprising
from 0.00005 to 0.05 wt% valerenic acid; and
from 0.00005 to 0.05 wt% of one or more flavones having the structure
Figure imgf000021_0001
wherein
the A-ring has at least one R1 group which is a -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof; and
R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or
6'.
2. A frozen confection according to claim 1 wherein the A-ring has four R1 groups.
3. A frozen confection according to claim 1 wherein the A-ring has two R1 groups attached to carbon atoms 8 and 6.
4. A frozen confection according to claim 1 wherein the A-ring has one R1 group attached to either carbon atom 8 or 6.
5. A frozen confection according to any of claims 1 to 4 wherein the R2 group is an -OH group, more preferably an -H group.
6. A frozen confection according to any of claims 1 to 5 wherein R3 group is an -OCH3 group, more preferably an -OH group, most preferably an -H group.
7. A frozen confection according to any of claims 1 to 6 wherein the flavone is selected from the group consisting of Wogonin, Hispidulin, and Tangeretin.
8. A frozen confection according to any of claims 1 to 7 wherein the frozen confection comprises at least 0.0001 wt% valerenic acid.
9. A frozen confection according to any of claims 1 to 7 wherein the frozen confection comprises at least 0.0001 wt% of the one or more flavones
10. A frozen confection according to any of claims 1 to 9 wherein the frozen confection comprises at least 0.00001 wt% GABA.
1 1 . A product for the potentiation of the GABA receptor wherein the product comprises a combination of valerenic acid and one or more flavones having the structure
Figure imgf000023_0001
wherein
the A-ring has at least one R1 group which is an -OCH3 group attached to any of carbon atoms 5, 6, 7, or 8;
- R2 is -H, -OH, an alkyl, an alkene, or derivatives thereof; and
R3 is -H, -OH, or -OCH3 and is attached to any of carbon atoms 2', 3', 4', 5', or 6' and wherein the ratio of the valerenic acid to the flavone is from 20:80 to 80:20.
12. A product according to claim 1 1 wherein the ratio of the valerenic acid to the flavone is at least 30:70.
13. A product according to claims 1 1 or 12 wherein the ratio of the valerenic acid to the flavone is at most 70:30
14. A product according to any of claims 1 1 or 13 wherein the valerenic acid and the flavone are present in approximately equal amounts.
15. A product for the enhancement of mood comprising the product of claim 1 1 .
PCT/EP2013/069934 2012-09-28 2013-09-25 Frozen confection comprising valerenic acid and one or more flavones WO2014048968A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12186620.6 2012-09-28
EP12186620 2012-09-28

Publications (1)

Publication Number Publication Date
WO2014048968A1 true WO2014048968A1 (en) 2014-04-03

Family

ID=47018839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/069934 WO2014048968A1 (en) 2012-09-28 2013-09-25 Frozen confection comprising valerenic acid and one or more flavones

Country Status (1)

Country Link
WO (1) WO2014048968A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061678A1 (en) * 2002-01-25 2003-07-31 Universtiy Of Strathclyde Sedative materials and treatments
WO2005115377A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
JP2005348656A (en) 2004-06-10 2005-12-22 Pharma Foods International Co Ltd Food and drink having relaxation effect
JP2009051738A (en) * 2007-08-23 2009-03-12 Yasuhara Chemical Co Ltd Method for producing polymethoxyflavones, polymethoxyflavones produced thereby and aqueous solution of organic acid containing polymethoxyflavones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061678A1 (en) * 2002-01-25 2003-07-31 Universtiy Of Strathclyde Sedative materials and treatments
WO2005115377A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
JP2005348656A (en) 2004-06-10 2005-12-22 Pharma Foods International Co Ltd Food and drink having relaxation effect
JP2009051738A (en) * 2007-08-23 2009-03-12 Yasuhara Chemical Co Ltd Method for producing polymethoxyflavones, polymethoxyflavones produced thereby and aqueous solution of organic acid containing polymethoxyflavones

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"GABA", vol. 54, 1 January 2006, ELSEVIER, ISBN: 978-0-12-032957-1, ISSN: 1054-3589, article GRAHAM A.R. JOHNSTON ET AL: "Modulation of Ionotropic GABA Receptors by Natural Products of Plant Origin", pages: 285 - 316, XP055055265, DOI: 10.1016/S1054-3589(06)54012-8 *
"How ice cream tickles your brain", THE GUARDIAN, 29 April 2005 (2005-04-29)
ABDOU ET AL.: "Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans", BIOFACTORS, vol. 26, no. 3, 2006, pages 201 - 208
DATABASE WPI Week 200923, Derwent World Patents Index; AN 2009-F79026, XP002693457 *
SIEGHART, W., PHARMACOLOGICAL REVIEWS, vol. 47, no. 2, 1995, pages 181 - 234
SMIT ET AL., PSYCHOPHARMACOLOGY, vol. 176, 2004, pages 412 - 419

Similar Documents

Publication Publication Date Title
Fedotova et al. Therapeutical strategies for anxiety and anxiety-like disorders using plant-derived natural compounds and plant extracts
Cheng et al. Evaluation of anxiolytic potency of essential oil and S-(+)-linalool from Cinnamomum osmophloeum ct. linalool leaves in mice
Tao et al. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway
Macready et al. Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies
Guerra-Araiza et al. Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases
Scapagnini et al. Antioxidants as antidepressants: fact or fiction?
Tasset et al. Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model
Klaus et al. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation
Wasowski et al. Flavonoids as GABAA receptor ligands: the whole story?
Rahman et al. Effects of anthocyanins on psychological stress-induced oxidative stress and neurotransmitter status
Souza-Monteiro et al. Antidepressant and antiaging effects of açaí (Euterpe oleracea Mart.) in mice
CA3080468A1 (en) Cannabinoid formulations
Singh et al. Anti-depressant like effects of quercetin 4'-O-glucoside from Allium cepa via regulation of brain oxidative stress and monoamine levels in mice subjected to unpredictable chronic mild stress
Vauzour Polyphenols and brain health
Redivo et al. Effect of omega-3 polyunsaturated fatty acid treatment over mechanical allodynia and depressive-like behavior associated with experimental diabetes
Oberholzer et al. Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat
Chandrasekhar et al. Tannins from Terminalia chebula fruits attenuates GABA antagonist-induced anxiety-like behaviour via modulation of neurotransmitters
Choi et al. Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model
Ajagun‐Ogunleye et al. Evaluation of the anti‐aging and antioxidant action of Ananas sativa and Moringa oleifera in a fruit fly model organism
Caraci et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against β-amyloid toxicity
Mustafa et al. Stingless Bee Honey Improves Spatial Memory in Mice, Probably Associated with Brain‐Derived Neurotrophic Factor (BDNF) and Inositol 1, 4, 5‐Triphosphate Receptor Type 1 (Itpr1) Genes
US20100048688A1 (en) Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses
Pizarro Melendez et al. Impact of polyphenols on stress and anxiety: a systematic review of molecular mechanisms and clinical evidence
Youssef et al. Antidepressant‐like effects of aqueous extracts of miswak (Salvadora persica) and date palm (Phoenix dactylifera) on depression‐like behaviors using CUMS model in male rats
TW201733619A (en) Composition for inhibiting carnosine dipeptidase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13766340

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13766340

Country of ref document: EP

Kind code of ref document: A1